| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Breast Cancer |
Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain
Key Words. Epothilones • Review • Breast cancer
Correspondence: Javier Cortes, M.D., Department of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. Telephone: 0034-948-296696; Fax: 0034-948-255500; e-mail: jacortes{at}vhebron.net
Microtubule-targeting agents such as the taxanes are highly active against breast cancer and have become a cornerstone in the treatment of patients with early and advanced breast cancer. The natural epothilones and their analogs are a novel class of microtubule-stabilizing agents that bind tubulin and result in apoptotic cell death. Among this family of compounds, patupilone, ixabepilone, BMS-310705, ZK-EPO, and KOS-862 are in clinical development. Extensive preclinical studies have shown that epothilones are working through partially nonoverlapping mechanisms of action with taxanes. In the clinic, epothilones have been found in a series of phase I and phase II studies to be active even in patients who had recently progressed to taxanes. The toxicity profile of these agents consists mostly of sensory neuropathy, sometimes reversible. Neoadjuvant studies with epothilones have been conducted and a number of phase III studies in advanced breast cancer are either under way or have been recently completed. The results of these studies are eagerly awaited and it is anticipated that epothilones may become an important treatment option in patients with breast cancer.
Disclosure of potential conflicts of interest is found at the end of this article.
This article has been cited by other articles:
 |
|
 |
|
  L. B. Michaud The Epothilones: How Pharmacology Relates to Clinical Utility Ann. Pharmacother., July 1, 2009; 43(7): 1294 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Boehnke Michaud The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer Journal of Oncology Pharmacy Practice, June 1, 2009; 15(2): 95 - 106. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Moreno-Aspitia and E. A. Perez Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane Mayo Clin. Proc., June 1, 2009; 84(6): 533 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Goodin Ixabepilone: A novel microtubule-stabilizing agent for the treatment of metastatic breast cancer Am. J. Health Syst. Pharm., November 1, 2008; 65(21): 2017 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bhushan and C. M Walko Ixabepilone: A New Antimitotic for the Treatment of Metastatic Breast Cancer Ann. Pharmacother., September 1, 2008; 42(9): 1252 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Waddell Introduction Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S2 - S3. [Full Text] [PDF]
|
|
|
|
|
|
L. B. Michaud Treatment-experienced breast cancer Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S4 - S9. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Goodin Novel cytotoxic agents: Epothilones Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S10 - S15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G I Kingston Tubulin-Interactive Natural Products as Anticancer Agents Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 305 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Teicher Newer Cytotoxic Agents: Attacking Cancer Broadly Clin. Cancer Res., March 15, 2008; 14(6): 1610 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Lee and S. M. Swain The Epothilones: Translating from the Laboratory to the Clinic Clin. Cancer Res., March 15, 2008; 14(6): 1618 - 1624. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| THE ONCOLOGIST | STEM CELLS | CME | ALPHAMED PRESS JOURNALS |
